유방암 검진 검사 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the breast cancer screening tests market size is projected to be USD 3.21 billion in 2025, USD 3.46 billion in 2026, and reach USD 5.18 billion by 2031, growing at a CAGR of 8.42% from 2026 to 2031.

This report is Segmented by Screening Modality (Imaging-Based Tests, Blood-Based Biomarker Tests, Genetic & Genomic Tests, Wearable & AI-Enabled Screening), End User (Hospitals, Specialty Cancer Centers, Diagnostic Imaging Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Breast Cancer Screening Tests Market Trends and Insights

Rising Prevalence of Breast Cancer

Global incidence climbed to 2.3 million cases in 2024 and is projected to reach 2.9 million by 2030, a trajectory driven by aging demographics, urban lifestyle shifts, and broader diagnostic reach. The United States logged 310,000 new diagnoses in 2025, while China reported 420,000, underscoring the dual pressure of scale and urbanization. Disease onset before 50 now accounts for 12% of Western cases, prompting guideline bodies to lower the screening start age from 50 to 40 years. This policy change alone expands the breast cancer screening tests market by an estimated 25 million women. Mortality is falling by 1.3% annually in high-income regions thanks to earlier detection, yet stagnates in low-resource countries, where coverage remains below 20%, highlighting the opportunity for mobile and point-of-care modalities.

Favorable Government Screening Recommendations

The 2024 U.S. shift to age-40 biennial mammography lowers mortality 19% in women 40-49, pushing volume through the reimbursement pipeline. The U.K. added women 47-73, funding GBP 120 million for mobile vans and training. Japan mandated annual ultrasound for dense breast tissue, affecting 40% of its cohort, and swelling equipment demand. China is subsidizing 70% of rural exam costs for 50 million women, pairing subsidies with AI triage in county hospitals. Compliance frameworks such as the FDA's MQSA align volume with strict quality metrics.

Radiation-Exposure Concerns Among Patients

Modern mammography delivers 0.4 milligrays per view, yet 22-28% of surveyed women still cite radiation fear, often conflating CT doses with screening levels. Density notifications, while clinically useful, inadvertently raise anxiety and push some women toward costlier MRI. Vendor countermeasures include photon-counting detectors and contrast-enhanced techniques that can reduce dose by up to 40%.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advances In 3-D Mammography
2. Intensifying Public-Private Awareness Campaigns
3. High Cost of Advanced Imaging Equipment

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Imaging-based Tests retained 66.02% of the revenue in 2025, yet the breast cancer screening tests market for Blood-based Biomarker Tests is expanding the fastest at a 9.06% CAGR through 2031. Mammography generated 1.2 billion exams, with Digital Breast Tomosynthesis overtaking 2-D in the United States and nearing parity in Europe. Handheld ultrasound devices added 15 million Asia-Pacific screens, while fast MRI protocols halved scan time and reduced costs to USD 600, pushing the modality beyond high-risk cohorts. Guardant's Shield and Exact Sciences' CancerSEEK multi-cancer assays, priced around USD 995, now compete with MRI for high-risk women, securing payer pilots that could widen use once mortality endpoints mature. Multi-analyte panels integrating proteins, microRNAs, and ctDNA are lining up behind early adopters, though regulatory clarity will ultimately dictate uptake.

Complete Report Scope:

• By Screening Modality
  • Imaging-based Tests
    • Mammography
    • Digital Breast Tomosynthesis
    • Ultrasound
    • Magnetic Resonance Imaging
    • PET & Molecular Imaging
  • Blood-based Biomarker Tests
    • Liquid Biopsy (ctDNA)
    • Multi-analyte Protein Panels
    • microRNA Panels
  • Genetic & Genomic Tests
    • BRCA 1/2 Mutation Tests
    • Multi-gene Panels
    • Polygenic Risk Scores
  • Wearable & AI-enabled Screening
    • Smart-bra Sensors
    • Hand-held AI Ultrasound
• By End User
  • Hospitals
  • Specialty Cancer Centers
  • Diagnostic Imaging Centers
  • Ambulatory Care Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 41.08% revenue in 2025, backed by Medicare's USD 150-200 reimbursement per exam and a 2024 guideline shift that added 20 million eligible women. Three large states require dense-breast ultrasound coverage without cost-sharing, pushing supplemental volume. Canada invested CAD 180 million (USD 133 million) in DBT upgrades, boosting penetration from 22% to 38% in one year. Mexico's mobile-unit rollout achieved 50% higher early-detection rates than fixed-site screening. Persistent radiologist shortages of 2,000 by 2028 are keeping AI triage and cross-border teleradiology in demand.

Asia-Pacific is the fastest-growing region, with a 10.27% CAGR to 2031. China's Healthy China 2030 allocates CNY 50 billion (USD 7 billion) for screening expansion to 70% urban coverage. India's Ayushman Bharat added screening at 5,000 health centers, targeting 30 million women by 202. Japan, already at 50% participation, deploys combined mammography-ultrasound for dense tissue, while South Korea's program pilots AI in 200 municipal clinics. Radiologist density varies sharply from 0.8 per 100,000 in India to 8 in Japan, necessitating task shifting and cloud AI solutions.

Centralized invitation systems and free-of-charge protocols keep participation near 75%. Germany now reimburses MRI for women with >=20% lifetime risk, lifting MRI screens by 18%. The U.K. cleared a COVID backlog after AI cut read times by a quarter. France's dense-breast notification pilot raised diagnostic yield by 12% but also false positives by 8%, prompting protocol review. Spain began integrating liquid biopsy for BRCA carriers, detecting 15% more interval cancers. Elsewhere, donor-funded mobile programs seed infrastructure in Nigeria, Kenya, South Africa, Brazil, and Argentina, but still face out-of-pocket hurdles for 40-50% of target populations.

1. Agilent Technologies
2. Beckton Dickinson
3. Canon
4. Danaher Corp. (Cepheid & Leica)
5. Delphinus Medical Technologies Inc.
6. Exact Sciences Corp.
7. Roche
8. FUJIFILM Holdings Corp.
9. GE HealthCare Technologies Inc.
10. Guardant Health
11. Hologic
12. iCAD Inc.
13. Illumina
14. Kheiron Medical Technologies Ltd.
15. Konica Minolta
16. Koninklijke Philips
17. Myriad Genetics
18. Siemens Healthineers
19. Thermo Fisher Scientific
20. Volpara Health Technologies Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Breast Cancer
  • 4.2.2 Favorable Government Screening Recommendations
  • 4.2.3 Technological Advances In 3-D Mammography
  • 4.2.4 Intensifying Public-Private Awareness Campaigns
  • 4.2.5 AI Triage Tools Lowering Image-Reading Cost
  • 4.2.6 Employer-Funded Mobile Screening In Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 Radiation-Exposure Concerns Among Patients
  • 4.3.2 High Cost of Advanced Imaging Equipment
  • 4.3.3 False Positives Leading to Overdiagnosis
  • 4.3.4 Regulatory Uncertainty for Liquid-Biopsy Tests
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Screening Modality
  • 5.1.1 Imaging-based Tests
    • 5.1.1.1 Mammography
    • 5.1.1.2 Digital Breast Tomosynthesis
    • 5.1.1.3 Ultrasound
    • 5.1.1.4 Magnetic Resonance Imaging
    • 5.1.1.5 PET & Molecular Imaging
  • 5.1.2 Blood-based Biomarker Tests
    • 5.1.2.1 Liquid Biopsy (ctDNA)
    • 5.1.2.2 Multi-analyte Protein Panels
    • 5.1.2.3 microRNA Panels
  • 5.1.3 Genetic & Genomic Tests
    • 5.1.3.1 BRCA 1/2 Mutation Tests
    • 5.1.3.2 Multi-gene Panels
    • 5.1.3.3 Polygenic Risk Scores
  • 5.1.4 Wearable & AI-enabled Screening
    • 5.1.4.1 Smart-bra Sensors
    • 5.1.4.2 Hand-held AI Ultrasound
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Specialty Cancer Centers
  • 5.2.3 Diagnostic Imaging Centers
  • 5.2.4 Ambulatory Care Centers
  • 5.2.5 Other End Users
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 Agilent Technologies Inc.
  • 6.3.2 Becton, Dickinson and Co.
  • 6.3.3 Canon Medical Systems Corp.
  • 6.3.4 Danaher Corp. (Cepheid & Leica)
  • 6.3.5 Delphinus Medical Technologies Inc.
  • 6.3.6 Exact Sciences Corp.
  • 6.3.7 F. Hoffmann-La Roche AG
  • 6.3.8 FUJIFILM Holdings Corp.
  • 6.3.9 GE HealthCare Technologies Inc.
  • 6.3.10 Guardant Health Inc.
  • 6.3.11 Hologic Inc.
  • 6.3.12 iCAD Inc.
  • 6.3.13 Illumina Inc.
  • 6.3.14 Kheiron Medical Technologies Ltd.
  • 6.3.15 Konica Minolta Inc.
  • 6.3.16 Koninklijke Philips N.V.
  • 6.3.17 Myriad Genetics Inc.
  • 6.3.18 Siemens Healthineers AG
  • 6.3.19 Thermo Fisher Scientific Inc.
  • 6.3.20 Volpara Health Technologies Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment